Zipalertinib trial meets primary endpoint in lung cancer study

🌐 Investing.com (CY) —
Zipalertinib trial meets primary endpoint in lung cancer study

AI Summary

The Zipalertinib trial has successfully met its primary endpoint in a lung cancer study, signaling positive progress in cancer treatment research. This advancement may have important health implications for lung cancer patients.

Health Zipalertinib lung cancer clinical trial primary endpoint medical research cancer treatment

Read original source →